UNSPSC 51144121: Formetorex

This classification denotes an anorexiant with the molecular formula C10H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 30555LM9SQ, chemically known as formamide, n-(alpha-methylphenethyl)- (8ci) but more generally known as formetorex, which bears US NIH Compound Identifier 65614. European Medicines Agency schedules Formetorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07785MIG. The term FORMETOREX is an International Non-Proprietary Name.

UNSPSC 51144121 Formetorex, a Commodity code, encompasses pharmaceutical products and related drug management systems that state and local governments procure to support community health, emergency response, and pharmacy benefit programs. State and local buyers under this code are acquiring naloxone and drug deactivation systems for overdose response, generic pharmaceuticals and over-the-counter products for health facilities and employee benefit programs, and direct-to-manufacturer prescription fulfillment capabilities to optimize pharmacy operations and cost management. Issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and facilities.

Recent activity shows Seminole County, Florida issuing an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing an RFP for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026; and the Texas Health and Human Services Commission issuing an RFI on March 27, 2026, to explore direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative. The geographic spread includes Florida, Minnesota (with participating state and local governments across multiple states including Oregon), and Texas, representing both standalone county-level procurement and large multistate cooperative purchasing mechanisms. Vendors responding to these opportunities must demonstrate compliance with cGMP, DSCSA, FDA requirements, drug-free workplace certification, and E-Verify eligibility, with contracts typically structured as fixed-fee or negotiated net pricing arrangements and initial terms of two years with optional renewal.